Combining Epigenetic And Immune Therapy to Beat Cancer.
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Umbrella study structure to independently and simultaneously assess the effects of the
association of durvalumab and tazemetostat in multiple solid tumors.